07:00 , May 18, 2015 |  BC Week In Review  |  Company News

Calchan neurology news

Calchan transitioned from a virtual company and added Brenda Reynolds as CEO, Manjit Rahelu as COO and Zahid Ali as CSO. Reynolds and Rahelu had been with Convergence Pharmaceuticals Ltd. , which Biogen Inc. (NASDAQ:BIIB,...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

CNV2197944: Phase II started

Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) began a double-blind, placebo-controlled, crossover, Hungarian Phase II trial to evaluate 75 mg oral CNV2197944 thrice daily for 3 weeks in about 165 DPN patients. As part of its restructuring...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

CNV2197944: Phase II started

Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) began a double-blind, placebo-controlled Phase II trial to evaluate repeat doses of oral CNV2197944. As part of its restructuring in 2011, Convergence transferred rights to CNV2197944 to Calchan. Convergence is...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

CNV2197944: Phase I data

Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) reported data from a placebo-controlled, U.K. Phase I trial in healthy volunteers showing that multiple ascending-doses of oral CNV2197944 were well tolerated with few adverse events reported at doses that...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Clinical News

CNV2197944: Phase I started

Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) began a placebo-controlled, U.K. Phase I trial to evaluate multiple ascending-doses of oral CNV2197944 for 28 days in about 50 healthy volunteers. Convergence is developing CNV2197944 on behalf of Calchan,...
07:00 , Apr 18, 2011 |  BC Week In Review  |  Clinical News

CNV2197944: Phase I started

Convergence began a placebo-controlled, U.K. Phase I trial to evaluate single ascending-doses of oral CNV2197944 in 24 subjects. Convergence Pharmaceuticals Ltd. , Cambridge, U.K.   Product: CNV2197944   Business: Neurology   Molecular target: Calcium channel...
07:00 , Oct 18, 2010 |  BioCentury  |  Emerging Company Profile

Convergence: Toning down pain

Convergence Pharmaceuticals Ltd. believes its state-dependent ion channel inhibitors can provide effective analgesia for chronic pain without the side effects associated with tonic ion channel blockers. On the back of a L22.4 million ($35.4 million)...
23:49 , Oct 4, 2010 |  BC Extra  |  Financial News

Convergence launches with $35.4 million

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) spun out Convergence Pharmaceuticals Ltd. (Cambridge, U.K.), which raised $35.4 million in a series A round from Apposite Capital; New Leaf Venture; and SV Life Sciences. GSK transferred eight neurology compounds...